Sheehan D V
Department of Psychiatry, University of South Florida, USF Institute for Research in Psychiatry, Tampa 36613-4788, USA.
J Clin Psychiatry. 1999;60 Suppl 18:16-21.
Panic disorder is a prevalent psychiatric condition that often is chronic and rarely resolves without medical intervention. Many patients with panic disorder initially present with a variety of somatic symptoms, including chest pain, nausea, or dizziness, and patients frequently seek care in ambulatory care settings. Although panic disorder is classified as a single entity, it can have many dimensions and may be associated with significant morbidity. During the past 2 decades, there have been significant advances in the treatment of panic disorder, and a range of therapeutic choices is now available. Four classes of medications, including the selective serotonin reuptake inhibitors (SSRIs), high-potency benzodiazepines, tricyclic antidepressants, and monoamine oxidase inhibitors, may be considered for the management of patients with panic disorder. Emerging clinical data favor the SSRIs as first-line treatment for patients with panic disorder, and paroxetine and sertraline have been approved by the U.S. Food and Drug Administration for use in panic disorder. This article reviews the efficacy and safety of these treatments, as well as their relative merits and disadvantages, and assists the practicing clinician in choosing among the various pharmacotherapies to tailor therapy to each patient's individual needs.
惊恐障碍是一种常见的精神疾病,通常呈慢性病程,若不经医学干预则很少自行缓解。许多惊恐障碍患者最初表现为多种躯体症状,包括胸痛、恶心或头晕,且患者常前往门诊寻求治疗。尽管惊恐障碍被归类为单一疾病实体,但它具有多维度特点,可能伴有显著的发病率。在过去20年里,惊恐障碍的治疗取得了重大进展,目前有一系列治疗选择。四类药物,包括选择性5-羟色胺再摄取抑制剂(SSRI)、高效苯二氮䓬类药物、三环类抗抑郁药和单胺氧化酶抑制剂,可用于治疗惊恐障碍患者。新出现的临床数据支持将SSRI作为惊恐障碍患者的一线治疗药物,帕罗西汀和舍曲林已获美国食品药品监督管理局批准用于治疗惊恐障碍。本文回顾了这些治疗方法的疗效和安全性,以及它们各自的优缺点,以帮助临床医生在各种药物治疗方法中进行选择,根据每个患者的个体需求制定个性化治疗方案。